Collagenase offers a minimally invasive treatment option for patients and can be administered in an office setting.
is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications, three of which include: Dupuytren's contracture, Peyronie's disease, and frozen shoulder (adhesive capsulitis).
Collagenase is a drug that breaks down collagen in damaged tissue and helps healthy tissue to grow.
Collagenase ointment is a sterile enzymatic debriding ointment which contains 250 collagenase units per gram of white petrolatum USP.
The FDA's Arthritis Advisory Committee voted 12-0 that the treatment, collagenase Clostridium histolyticum, should be approved for treating advanced Dupuytren's, based on the available safety and efficacy data.
In double-blind studies of patients with advanced Dupuytren's, significantly greater proportions of patients treated with collagenase Clostridium had almost a complete reduction in contractures, compared with those who received placebo.
Follow-up tests showed that the tetracycline disarmed the collagenase
made by certain immune system cells that contribute to inflammation, but other antibiotics had no effect.
1 Collagenase clostridium histolyticum is the first injectable treatment to be approved in the EU for the treatment of Dupuytren's contracture.
The EU approval of collagenase clostridium histolyticum is based on results from two pivotal studies, Collagenase Option for Reduction of Dupuytren's (CORD I and CORD II).
NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that there will be three separate presentations on collagenase clostridium histolyticum (trademarked XIAPEX in Europe) for the treatment of patients suffering from Dupuytren's contracture at the upcoming XVI Annual Federation of the European Societies for Surgery of the Hand Meeting to be held in Oslo, Norway at the Oslo Congress Centre on May 26-28, 2011.
Friday, May 27th, 2011, 2:24 PM CEST (8:24 AM EDT) Location: Hall A, OPS 140 / A-0287 Session 13: Dupuytren's Presentation Title: Efficacy and tolerability of collagenase clostridium histolyticum in European patients with Dupuytren's contracture: Results from a multicenter, open-label study Presenters: J.
Collagenases are routinely utilized in the isolation and preparation of therapeutic cells.
We are looking forward to initiating a new clinical trial in lipomas and working on improved collagenase in the field of tissue disassociation.
This peptide target showed evidence of activating the production of collagenase
, an enzyme that destroys cartilage.
M(r) 92,000 type IV collagenase
is increased in plasma of patients with colon cancer and breast cancer.